Table 2 Baseline clinical characteristics of the population used in the experimental verification groups
T2DM (n = 126) | T2DM + AMI (n = 122) | P value | |
|---|---|---|---|
Age, years | 63 (57–76) | 62 (55–70) | 0.684 |
Male gender, n (%) | 54 (42.9) | 89 (73) | < 0.001 |
BMI, Kg/m2 | 26.46 (23.64–28.58) | 25.95 (24.17–27.71) | 0.283 |
Smoking, n (%) | 24 (19) | 75 (61.5) | < 0.001 |
Hypertension, n (%) | 40 (31.7) | 76 (62.3) | < 0.001 |
Dyslipidemia, n (%) | 78 (61.9) | 65 (53.3) | 0.169 |
Duration of diabetes, years | 9.0 (3.0–15.0) | 10.0 (3.3–15.0) | 0.811 |
Laboratory values | |||
Cr, umol/L | 62.05 (53.03–71.28) | 73.40 (60.08–82.63) | 0.001 |
TC, mmol/L | 3.99 (3.31–4.60) | 4.46 (3.85–5.04) | < 0.001 |
TG, mmol/L | 1.38 (1.06–1.97) | 1.36 (1.02–2.08) | 0.697 |
HDL-C, mmol/L | 1.06 (0.92–1.27) | 0.96 (0.86–1.14) | 0.014 |
LDL-C, mmol/L | 2.20 (1.69–2.65) | 2.65 (2.28–3.10) | < 0.001 |
Hs-CRP, mg/L | 1.00 (0.46–2.97) | 13.25 (2.57–29.29) | < 0.001 |
HbA1c, % | 6.80 (6.20–7.50) | 7.90 (6.95–9.13) | < 0.001 |
Fasting glucose, mmol/L | 6.60 (5.46–7.54) | 9.24 (6.71–12.34) | < 0.001 |
CK-MB, ng/ml | 1.00 (0.70–1.55) | 5.15 (1.93–20.35) | < 0.001 |
cTNI, ng/ml | 0 (0–0) | 0.67 (0.66–6.93) | < 0.001 |
Medical therapies before admission | |||
Antiplatelet agent, n (%) | 32 (25.4) | 24 (19.7) | 0.281 |
Statin, n (%) | 45 (35.7) | 12 (9.8) | < 0.001 |
ACEI/ARB, n (%) | 63 (50) | 35 (28.7) | < 0.001 |
Diuretics, n (%) | 14 (11.1) | 7 (5.7) | 0.129 |
Acarbose, n (%) | 42 (33.3) | 54 (44.3) | 0.077 |
Metformin, n (%) | 76 (60.3) | 44 (36.1) | < 0.001 |
Sulfonylurea, n (%) | 33 (26.2) | 29 (23.8) | 0.660 |
Insulin, n (%) | 29 (23) | 30 (24.6) | 0.771 |
Insulin sensitizers, n (%) | 10 (7.9) | 4 (3.3) | 0.112 |
DPP-4 inhibitors, n (%) | 5 (4) | 2 (1.6) | 0.268 |